BIOA B — BioArctic AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK26.00bn
- SEK24.10bn
- SEK2.00bn
Brief: BioArctic Says CHMP Issues Positive Recommendation For Approval Of Lecanemab In The EU
Brief: BioArctic Q3 Operating Profit SEK -26.1 Million
Brief: Bioarctic AB Says Eisai Expects Leqembi Sales To Reach JPY 42.5 Billion for FY.
Brief: Eisai Completes Rolling BLA Submission For Subcutaneous Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) In The Us
Brief: Leqembi® Q3 Revenue Totaled Jpy 10 Billion
Brief: Eisai Will Request Reconsideration Of Initial Decision For Lecanemab In Australia
Brief: BioArctic Q2 Operating Profit SEK -75.8 Million
Brief: BioArctic Study Results From Phase 1 Studies With Exidavnemab
Brief: NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England
Brief: Bioarctic's Leqembi Approved In UK For Treatment Of Early Alzheimer's
Brief: UK's MHRA Approves Eisai-Biogen's Alzheimer's drug
Brief: UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS
Brief: Bioarctic Updates Regarding Rumors Of Imminent Approval Of Lecanemab In Great Britain
Brief: Leqembi Approved For The Treatment Of Alzheimer's Disease In The UAE
Brief: BioArctic Says Leqembi Approved For The Treatment Of Alzheimer's Disease In UAE
Brief: Bioarctic says Long-Term Lecanemab Data Show Increased Patient Benefit With Maintained Safety Profile
Brief: Committee For Medicinal Products Has Adopted Negative Opinion On BioArctic's Lecanemab For EU
Brief: BioArctic's Leqembi Approved For Treatment Of Alzheimer's In Israel
Brief: Bioarctic Says Co & Eisai Announced Today That Leqembi Has Been Approved For Treatment Of Alzheimer's Disease In Israel